Blog

When to conduct hepatic impairment studies and when modeling may be enough

How to decide if a hepatic impairment study is required, choose the right study design,…

Zoe BarterJuly 13, 2026

Conference

ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop

Matt Zierhut, PhD MBAJuly 9, 2026

Blog

Dosimetry for radiopharmaceutical therapy: From measurement to dose justification

Why dosimetry for radiopharmaceutical therapy needs more than absorbed dose. How BED, radiation dosimetry &…

Hunter Stephens, PhDJuly 7, 2026

Blog

Enhancing clinical trials with real-world evidence in pregnancy research

Learn how real-world evidence improves clinical trials in pregnancy by enhancing safety data, trial design,…

Alekhya Lavu, PhD, PharmDJune 26, 2026

Guide

How to Build a Best Practice Global Value Dossier With a Decision-first Strategy

Learn how a decision-first approach to value dossier preparation helps teams build pharma value dossiers…

CertaraJune 25, 2026

Poster

Development of a human PBMC TXG-MAPr as a mechanistic framework to interpret toxicodynamic variability across the human population

Leiden University and EFSA researchers present the PBMC TXG-MAPr — a network-based transcriptomic tool mapping…

CertaraJune 23, 2026

Poster

Characterization of human toxicodynamic variability using peripheral blood mononuclear cells from a large cohort of healthy volunteers

Research from Leiden University and EFSA characterizing interindividual toxicodynamic variability using peripheral blood mononuclear cells…

CertaraJune 23, 2026

Announcement

Certara Launches Bio Venture Catalyst for Emerging Biotechs to De-risk Investment and Accelerate Development

Integrated offering combines drug development, regulatory, commercial, and investor strategy expertise to help early-stage biotech…

Danielle PillsburyJune 23, 2026

Poster

Integrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodies

Discover how endogenous ligand competition was incorporated into a whole-body PBPK model to improve prediction…

CertaraJune 23, 2026

Poster

Application of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Study

Learn how Certara's IO Simulator was used to predict efficacy, cytokine release syndrome risk, and…

CertaraJune 23, 2026

Certara Services

When to conduct hepatic impairment studies and when modeling may be enough

ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop

Dosimetry for radiopharmaceutical therapy: From measurement to dose justification

Enhancing clinical trials with real-world evidence in pregnancy research

How to Build a Best Practice Global Value Dossier With a Decision-first Strategy

Development of a human PBMC TXG-MAPr as a mechanistic framework to interpret toxicodynamic variability across the human population

Characterization of human toxicodynamic variability using peripheral blood mononuclear cells from a large cohort of healthy volunteers

Certara Launches Bio Venture Catalyst for Emerging Biotechs to De-risk Investment and Accelerate Development

Integrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodies

Application of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Study

Newsletter sign up

Quick links

Solutions

Contact